

Home / Investors/ News Releases

## Insmed To Present at the 40th Annual J.P. Morgan Healthcare Conference

BRIDGEWATER, N.J., Jan. 4, 2022 /<u>PRNewswire</u>/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the virtual 40<sup>th</sup> Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 3:45 p.m. ET.

The presentation and question and answer session will be webcast live and can be accessed by visiting the investor relations section of the Company's website at <a href="https://www.insmed.com">www.insmed.com</a>. The webcast will be archived for a period of 30 days following the conclusion of the live event.

## **About Insmed**

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a growing footprint across Europe and in Japan. For more information, visit <a href="https://www.insmed.com">www.insmed.com</a>.

## **Contact:**

Investors:

Eleanor Barisser Associate Director, Investor Relations Insmed (718) 594-5332 eleanor.barisser@insmed.com

Media:

Mandy Fahey Senior Director, Corporate Communications Insmed (732) 718-3621 amanda.fahey@insmed.com

SOURCE Insmed Incorporated